Nifedipine 4 mg/mL oral suspension

Opaque suspension.

References: [1]

Dihydropyridine calcium-channel blocker; the liquid dosage form requires a specific clinical decision.
Active-drug context from another product’s labelling; it does not establish stability or dosing of this compounded preparation.

References: [2]

Final-product visual inspection. The institutional sheet gives no specific numerical limits.

References: [1]

For the finished product the source specifies:
Tight, light-resistant plastic container. Source prefers refrigeration and permits room temperature, without a numerical range.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

Complete formula-specific PPE is not specified. Select gloves, eye protection and exposure controls using the exact materials’ SDS and the local risk assessment.
Supplementary AEMPS framework: clean long-sleeved laboratory clothing, hair covering and dedicated footwear/overshoes. Powder handling requires suitable eye/respiratory protection; change gloves with activity or damage. Select the exact type/material using SDS and risk assessment.

References: [1] · [3]

A complete formula-specific hazard classification is not established. Assess potency, dust/aerosol, allergens, solvents, microbial risk and cross-contamination using the actual materials and process. Absence of a flag does not establish absence of hazard.

References: [1]

Follow the addition sequence, temperatures and times stated under Preparation Procedure. The specific monograph is not a complete qualification of the local facility/equipment.

References: [1]

Source period: 90 days.
The source period applies to its exact composition, method and packaging. It is not this batch’s expiry date and cannot be transferred to another vehicle/strength. Calculate the actual date in the blank batch record.

References: [1]

No separate base is identified in the dependency register. Check any commercial vehicles/compound excipients listed in the formula.

References: [1]

Indicative checklist derived from the method: Balance of suitable resolution, Containers and mixing tools compatible with the materials, Calibrated pH meter. Selection/qualification is defined locally.

References: [1]

Weigh nifedipine powder immediately before compounding. Levigate with a little SyrSpend SF PH4 Cherry and dilute progressively. Transfer quantitatively with rinses, make to 30 mL and mix. Package immediately after verification.

References: [1]

Photosensitive: compound immediately after weighing and package immediately after verification. Applies to bulk powder and this exact Cherry vehicle, not every SyrSpend product.

References: [1]

Light-resistant plastic bottle as specified by the sheet.

References: [1]

Visually examine the final product against the stated appearance. The sheet supplies no validated assay method or numerical microbiological limit.

References: [1]

Tight, light-resistant plastic container. Source prefers refrigeration and permits room temperature, without a numerical range.

References: [1]

No additional special directions are established beyond the source route, storage and notes. Complete patient details, dose and directions from the prescription.

References: [1]

Nifedipine 4 mg/mL oral suspension
Strength/variant: __________ Quantity: __________
Batch: __________ Prepared: __________ Use by: __________
Από του στόματος / Oral use
Dose/directions: __________
Storage: Tight, light-resistant plastic container. Source prefers refrigeration and permits room temperature, without a numerical range.
Shake before use.

References: [1]